Astellas Pharma (ALPMY) News Today $9.69 -0.04 (-0.41%) As of 07/18/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock ALPMY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"July 16, 2025 | prnewswire.comChinese court sentences a Japanese man to more than 3 years in prison on espionage chargesA Japanese man has been sentenced to three and a half years in prison in China on espionage charges...July 16, 2025 | marketbeat.comAstellas Pharma Inc. (ALPMY) Income Statement - Yahoo FinanceJuly 10, 2025 | finance.yahoo.comALPMY Astellas Pharma Inc. - Seeking AlphaJuly 8, 2025 | seekingalpha.comAstellas Pharma Inc Analysis & Opinion (ALPMY) - Investing.comJuly 2, 2025 | investing.comAstellas Pharma’s New Study on ASP3021: A Potential Game-Changer for AMD TreatmentJune 24, 2025 | msn.comAstellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?June 14, 2025 | marketbeat.comMitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in JapanJune 13, 2025 | prnewswire.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 555.2% in MayJune 11, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Stock Price Passes Above 50-Day Moving Average - Here's What HappenedJune 6, 2025 | marketbeat.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Drops By 62.9%May 30, 2025 | marketbeat.comAstellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2May 29, 2025 | prnewswire.comAstellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and CaregiversMay 28, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Shares Cross Above 50-Day Moving Average - Here's WhyMay 24, 2025 | marketbeat.comAstellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna BioMay 21, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below 50-Day Moving Average - What's Next?May 16, 2025 | marketbeat.comAstellas CEO Says Engaging With Activist Investor FarallonMay 7, 2025 | bloomberg.comAstellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Above 50-Day Moving Average - Here's What HappenedMay 4, 2025 | marketbeat.comAstellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual CongressesMay 1, 2025 | prnewswire.comAstellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call TranscriptApril 28, 2025 | seekingalpha.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Decreases By 98.5%April 28, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPSApril 28, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Stock Crosses Above 50-Day Moving Average - What's Next?April 25, 2025 | marketbeat.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest UpdateApril 16, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Sets New 1-Year Low - Here's WhyApril 12, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Reaches New 12-Month Low - Here's What HappenedApril 8, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Reaches New 52-Week Low - What's Next?April 6, 2025 | marketbeat.comAstellas Pharma and JFCR partner for oncology researchApril 3, 2025 | msn.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 56.7% in MarchMarch 28, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Shares Pass Above 50-Day Moving Average - Here's What HappenedMarch 26, 2025 | marketbeat.comSinglera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT MeetingMarch 24, 2025 | globenewswire.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Rises By 20.8%March 18, 2025 | marketbeat.comAstellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline ForwardMarch 15, 2025 | seekingalpha.comAstellas Pharma (OTCMKTS:ALPMY) Stock Passes Above 50-Day Moving Average - Should You Sell?March 11, 2025 | marketbeat.comJ.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)March 8, 2025 | markets.businessinsider.comAstellas and Yaskawa form JV for cell therapy product manufactureMarch 7, 2025 | finance.yahoo.comAstellas and YASKAWA form JV focused on cell therapy manufacturingMarch 6, 2025 | msn.comAstellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy ManufacturingMarch 5, 2025 | finance.yahoo.comAstellas Pharma (OTCMKTS:ALPMY) Stock Crosses Below 200-Day Moving Average - Here's WhyMarch 2, 2025 | marketbeat.comAstellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator PrizeFebruary 27, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?February 22, 2025 | marketbeat.comAstellas Pharma Inc.: U.S. FDA Approves Expanded Label for Astellas' IZERVAY (avacincaptad pegol intravitreal solution) for Geographic AtrophyFebruary 13, 2025 | finanznachrichten.deShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Increases By 132.4%February 13, 2025 | marketbeat.comU.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic AtrophyFebruary 12, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Below 50 Day Moving Average - Here's WhyFebruary 12, 2025 | marketbeat.comPfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. ChemoFebruary 11, 2025 | finance.yahoo.comAstellas seeks conditional approval for GA treatment in JapanFebruary 5, 2025 | finance.yahoo.comAstellas Pharma Submits NDA For Avacincaptad Pegol For Geographic Atrophy In JapanFebruary 5, 2025 | markets.businessinsider.comAstellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in JapanFebruary 5, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Releases Earnings ResultsFebruary 4, 2025 | marketbeat.com Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPMY Media Mentions By Week ALPMY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALPMY News Sentiment▼-0.820.61▲Average Medical News Sentiment ALPMY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALPMY Articles This Week▼22▲ALPMY Articles Average Week Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RCDTF News Today SLN News Today UCBJY News Today CHGCY News Today ZTS News Today TAK News Today DSNKY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ALPMY) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALPMY Stock Alerts